Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis

Neoplasia

Volumn 12, Issue 12, 2010, Pages 980-992

  Bera, Soumen ^a   Greiner, Suzanne ^b   Choudhury, Amit ^a   Dispenzieri, Angela ^c   Spitz, Douglas R ^a   Russell, Stephen J ^b   Goel, Apollina ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Molecular Medicine Program   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; COPPER ZINC SUPEROXIDE DISMUTASE; DEXAMETHASONE; INTERLEUKIN 6; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IRRADIATION; MOUSE; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; SURVIVAL TIME;

EID: 78649861169     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101146     Document Type: Article

References (63)

1. Mill WB (1975). Radiation therapy in multiple myeloma. Radiology 115, 175-178.
2. Bosch A and Frias Z (1988). Radiotherapy in the treatment of multiple myeloma. Int J Radiat Oncol Biol Phys 15, 1363-1369.
3. Kilciksiz S, Celik OK, Pak Y, Demiral AN, Pehlivan M, Orhan O, Tokatli F, Agaoglu F, Zincircioglu B, Atasoy BM, et al. (2008). Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol 83, 702-707.
4. Lewanski CR, Bates T, Bowen J, and Ashford RF (1999). Solitary bone plasmacytoma: management of isolated local relapse following radiotherapy. Clin Oncol (R Coll Radiol) 11, 348-351.
5. Goel A, Dispenzieri A, Witzig TE, and Russell SJ (2006). Enhancing the ther- apeutic index of radiation in multiple myeloma. Drug Discov Today Dis Mech 3, 515-522.
6. Chatterjee M, Chakraborty T, and Tassone P (2006). Multiple myeloma: mono- clonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur J Cancer 42, 1640-1652.
7. Wong JY, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J, Essensten M, Forman S, and Somlo G (2006). Targeted total marrow irradiation using three- dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant 12,306-315.
8. Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, and Somlo G (2009). Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 73, 273-279.
9. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, and Bruland OS (2002). High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20, 189-196.
10. Dispenzieri A, Wiseman GA, Lacy MQ, Geyer S, Litzow MR, Tefferi A, Inwards DJ, Micallef IN, Ansell S, Gastineau DA, et al. (2003). A phase II study of high dose 153-samarium EDTMP (153-sm EDMTP) and melphalan for peripheral stem cell transplantation (PBSCT) in multiple myeloma (MM). Blood 102, 982a-a.
11. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, et al. (2010). A phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 85, 409-413.
12. Abruzzese E, Iuliano F, Trawinska MM, and Di Maio M (2008). 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin Investig Drugs 17,1379-1387.
13. Marchand V, Decaudin D, Servois V, and Kirova YM (2008). Concurrent radiation therapy and lenalidomide in myeloma patient. Radiother Oncol 87, 152-153.
14. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, and Swift RA (2009). A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 15, 1069-1075.
15. Berges O, Decaudin D, Servois V, and Kirova YM (2008). Concurrent radiation therapy and bortezomib in myeloma patient. Radiother Oncol 86, 290-292.
16. Palumbo A and Gay F (2009). How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology Am Soc Hematol Educ Program, 566-577.
17. Turesson I, Velez R, Kristinsson SY, and Landgren O (2010). Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 85,225-230.
18. Alexanian R, Dimopoulos MA, Delasalle K, and Barlogie B (1992). Primary dexamethasone treatment of multiple myeloma. Blood 80, 887-890.
19. Rajkumar SV, Gertz MA, Kyle RA, and Greipp PR (2002). Current therapy for multiple myeloma. Mayo Clin Proc 77, 813-822.
20. Frankfurt O and Rosen ST (2004). Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 16, 553-563.
21. Greenstein S, Ghias K, Krett NL, and Rosen ST (2002). Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 8, 1681-1694.
22. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, et al. (2000). SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 275, 27845-27850.
23. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352, 2487-2498.
24. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, et al. (2010). Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28, 132-135.
25. Spitz DR, Azzam EI, Li JJ, and Gius D (2004). Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 23, 311-322.
26. Grigorieva I, Thomas X, and Epstein J (1998). The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 26, 597-603.
27. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, and Farrar WL (2004). NF-κB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFκB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther 3, 1007-1017.
28. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332, 83-85.
29. Hodge DR, Xiao W, Peng B, Cherry JC, Munroe DJ, and Farrar WL (2005). Enforced expression of superoxide dismutase 2/manganese superoxide dismutase disrupts autocrine interleukin-6 stimulation in human multiple myeloma cells and enhances dexamethasone-induced apoptosis. Cancer Res 65, 6255-6263.
30. Kuku I, Aydogdu I, Bayraktar N, Kaya E, Akyol O, and Erkurt MA (2005). Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct 23, 47-50.
31. Sharma A, Tripathi M, Satyam A, and Kumar L (2009). Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma 50, 809-815.
32. Zima T, Spicka I, Stipek S, Crkovska J, Platenik J, Merta M, Nemecek K, and Tesar V (1996). Lipid peroxidation and activity of antioxidative enzymes in patients with multiple myeloma. Cas Lek Cesk 135, 14-17.
33. Baker AF, Briehl MM, Dorr R, and Powis G (1996). Decreased antioxidant defence and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity. Cell Death Differ 3, 207-213.
34. Briehl MM, Cotgreave IA, and Powis G (1995). Downregulation of the anti- oxidant defence during glucocorticoid-mediated apoptosis. Cell Death Differ 2, 41-46.
35. Jaramillo MC, Frye JB, Crapo JD, Briehl MM, and Tome ME (2009). Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res 69, 5450-5457.
36. Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, and Anderson KC (2003). Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene 22, 6296-6300.
37. Burington B, Barlogie B, Zhan F, Crowley J, and Shaughnessy JD Jr (2008). Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 14, 4821-4829.
38. Dandona P, Mohanty P, Hamouda W, Aljada A, Kumbkarni Y, and Garg R (1999). Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study. Clin Pharmacol Ther 66, 58-65.
39. Ferrigno A, Gregotti C, Richelmi P, and Vairetti M (2010). Dexamethasone protects cultured rat hepatocytes against cadmium toxicity: involvement of cellular thiols. In Vitro Cell Dev Biol Anim 46, 445-449.
40. Baumeister P, Korn G, Berghaus A, Matthias C, and Harreus U (2009). Chemopreventive action of dexamethasone and alpha-tocopherol in oxidative stressed cells. Cancer Detect Prev 32, 452-457.
41. Wang Y, Liu L, Pazhanisamy SK, Li H, Meng A, and Zhou D (2010). Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Radic Biol Med 48, 348-356.
42. Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, and Russell SJ (2006). Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 107, 4063-4070.
43. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, and Russell SJ (2005). PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 33, 784-795.
44. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT, Bell JC, and Russell SJ (2007). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110, 2342-2350.
45. Schmidmaier R, Baumann P, Emmerich B, and Meinhardt G (2006). Evaluation of chemosensitivity of human bone marrow stromal cells-differences between common chemotherapeutic drugs. Anticancer Res 26, 347-350.
46. Pessina A, Neri MG, Mineo E, Piccirillo M, Gribaldo L, Brambilla P, Zaleskis G, and Ujhazy P (1997). Expression of B cell markers on SR-4987 cells derived from murine bone marrow stroma. Exp Hematol 25, 536-541.
47. Hideshima T and Anderson KC (2002). Molecular mechanisms of novel ther- apeutic approaches for multiple myeloma. Nat Rev Cancer 2, 927-937.
48. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, et al. (2003). Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841.
49. Zhu Y, Kalen AL, Li L, Lehmler HJ, Robertson LW, Goswami PC, Spitz DR, and Aykin-Burns N (2009). Polychlorinated-biphenyl-induced oxidative stress and cytotoxicity can be mitigated by antioxidants after exposure. Free Radic Biol Med 47, 1762-1771.
50. Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, and Deeg HJ (1995). Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 31, 1319-1339.
51. Tome ME, Baker AF, Powis G, Payne CM, and Briehl MM (2001). Catalase- overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth. Cancer Res 61, 2766-2773.
52. von Lindern M, Zauner W, Mellitzer G, Steinlein P, Fritsch G, Huber K, Lowenberg B, and Beug H (1999). The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 94, 550-559.
53. Lewandowski D, Barroca V, Duconge F, Bayer J, Van Nhieu JT, Pestourie C, Fouchet P, Tavitian B, and Romeo PH (2010). In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution. Blood 115, 443-452.
54. Podar K, Richardson PG, Hideshima T, Chauhan D, and Anderson KC (2007). The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 20, 597-612.
55. Criswell T, Leskov K, Miyamoto S, Luo G, and Boothman DA (2003). Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22, 5813-5827.
56. Beetz A, Messer G, Oppel T, van Beuningen D, Peter RU, and Kind P (1997). Induction of interleukin 6 by ionizing radiation in a human epithelial cell line: control by corticosteroids. Int J Radiat Biol 72, 33-43.
57. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, and Haegeman G (1997). Glucocorticoid-mediated repression of nuclear factor-κB- dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 94, 13504-13509.
58. Ramdas J and Harmon JM (1998). Glucocorticoid-induced apoptosis and regulationofNF-κBactivityinhumanleukemicTcells.Endocrinology 139,3813-3821.
59. Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC, and Zuraw BL (2007). The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol 119,115-122.
60. Grugan KD, Ma C, Singhal S, Krett NL, and Rosen ST (2008). Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. J Steroid Biochem Mol Biol 110, 244-254.
61. Mittelstadt PR and Ashwell JD (2001). Inhibition of AP-1 by the glucocorticoid- inducible protein GILZ. J Biol Chem 276, 29603-29610.
62. Kyle RA and Rajkumar SV (2009). Treatment of multiple myeloma: a compre- hensive review. Clin Lymphoma Myeloma 9, 278-288.
63. Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, and Lonial S (2010). Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer 116, 3143-3151.